Lonza to Expand Cytotoxic API Capacity in Switzerland

Lonza says it will invest SF24 million ($27 million) to expand cytotoxic manufacturing capabilities at the company’s site at Visp, Switzerland. Cytotoxic active pharmaceutical ingredients (APIs) are widely used in oncology therapeutics, one of the fastest growing segments of the pharma and biotech industries, Lonza says. “This investment speeds our efforts to establish the Lonza Visp site as a center of excellence for high potency manufacturing,” says Stefan Stoffel, head of Lonza’s chemical manufacturing business unit. “With the...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers